A novel and successful therapeutic approach in the treatment of a patient with simultaneous relapsed Ewing sarcoma and therapy‐related acute myeloid leukemia

Abstract

Ewing sarcoma and therapy-related AML having sustained remissions for up to 1 year at the time of study publication, 13,14 and a recently closed phase II Children's Oncology Group Trial evaluated pazopanib in patients with relapsed or refractory Ewing sarcoma 15 (study results still pending). While McNew et al reported on a patient with t-AML that developed during primary therapy for Ewing sarcoma (with the patient dying shortly after diagnosis), 10 this is to our knowledge the first report of a patient with concurrent t-AML and relapsed Ewing sarcoma. At this time, the patient has achieved a 14-month remission with CPX-351, followed by TVTG, ASCT, and maintenance therapy with pazopanib.